Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About Alfama

Alfama specializes in the development of Carbon Monoxide-Releasing Molecules (CORMs) for therapy. The company produces CORMs and obtained exceptional results in various animal models of chronic and acute human diseases. CORMs have the potential to expand CO-based therapy to a wide range of high-value indications, can be administered orally or intravenously, and offer a very attractive therapeutic window and safety profile.

Headquarters Location

Taguspark Núcleo Central 267

Porto Salvo, 2740-122,


Missing: Alfama's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Alfama's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Alfama

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alfama is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Alfama Patents

Alfama has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Malaria, Plasmodium, Intensive care medicine, Respiratory therapy, Mechanical ventilation


Application Date


Grant Date



Related Topics

Malaria, Plasmodium, Intensive care medicine, Respiratory therapy, Mechanical ventilation



Latest Alfama News

British Tourists Return to Portugal, Unleashed but (Mostly) Masked

May 29, 2021

May 29, 2021, 5:00 a.m. ET After enduring a winter of strict lockdown, and a spring that saw a gradual reopening but lousy weather to spend it in, the first British tourists to Portugal since the country was “ green-listed ” for quarantine-free travel were elated by the thrill of escape, even if their trips were not quite as carefree as in past summers. “We just wanted to go anywhere that wasn’t London, basically,” said the singer and songwriter Celeste Waite, 27, as she climbed a hilly street in Lisbon’s Alfama district last Saturday with Sonny Hall, 22, a model and poet. “It’s been nice finally getting back to normal,” said Karen Kaur, 35, of Kent, England, after she and Jay Singh, 38, downed shots of ginjinha, a cherry liqueur, from a street vendor in Praça da Figueira, a large square in the city’s center. But British travelers expecting a kind of pre-pandemic travel experience found something different in Lisbon during the first weekend it reopened to them. Though the Portuguese capital still offered its signature food, museums, picturesque vistas and attractions, stringent mask rules and curfews reminded visitors this would not be an unfettered escape. The opening weekend for Britons offered a preview of what a broader return to international travel may look like for others, including vaccinated Americans when they are welcomed to Europe this summer: A mixture of joy, relief, and at times awkward interactions as cultures converge after a year of disparate pandemic experiences. Image Tourists soak up the sun in Cascais, a coastal resort town near Portugal’s capital of Lisbon. Before the pandemic, Britons were one of the town’s top tourist markets.Credit...Daniel Rodrigues for The New York Times Portugal has long been among Britain’s favorite tourist destinations, with scenic city escapes in Lisbon and Porto, and beachside restaurants and hotels catering to British tourists in the coastal resort town of Cascais and the Algarve, known for its alluring beaches, all within a three-hour flight. More than 2.1 million people visited from Britain in 2019, the most from any country except Spain, according to Turismo de Portugal, the national tourist board. Now, Portugal is one of Britain’s only tourist destinations. Earlier in May, Britain included Portugal on its “ green list ” of 12 countries and territories that residents could travel to from May 17 without quarantining for up to 10 days upon return. Most other green-listed places are either not accepting tourists or are not major destinations. Image A tourist passing the Casa de Santa Maria in Cascais. Britain added Portugal to its “green list,” which allowed its residents to travel there without quarantining from May 17.Credit...Daniel Rodrigues for The New York Times Prices for flights to Portugal spiked after the announcement. But flying now means accepting expensive, and, at times, confusing extra steps, highlighting the tentative nature of international travel’s reopening. Tourists need to fill out multiple forms and submit a negative PCR test taken less than 72 hours before the flight. Before returning to Britain, they must take another test within 72 hours of their flight, and prove they have booked a third test to be taken on their second day back in Britain. The tests add up to hundreds of dollars per person, for many people exceeding the cost of the flight. Some tourists on a British Airways flight from London last Saturday said the extra steps were a pain, but they needed to get out of Britain after a difficult winter. From December to late March, the country experienced one of the world’s strictest and longest nationwide lockdowns, with socializing permitted only through walks in the cold with one other person. Pubs and restaurants didn’t open for outdoor dining until mid-April, and overnight travel within the country wasn’t permitted until last week. “No one else is going, so I’ve been rubbing it in with my friends,” said Anna De Pascalis, 23, before boarding a flight to Lisbon with her mother, Julie De Pascalis. “Everyone’s pretty jealous.” After a winter of rising coronavirus cases, Portugal has been down to a few hundred cases and single-digit deaths per day since late March. But there is a disparity in inoculations against Covid-19: About 36 percent of Portuguese people have received at least one dose of a vaccine, compared to about 57 percent of those from the United Kingdom. Image Tourists enjoying the view from São Jorge Castle, a popular attraction in Lisbon. A mere trickle of tourists have returned to Portugal so far compared to the hordes before the pandemic.Credit...Ana Brigida for The New York Times Silvia Olivença, the owner of the food tour company Oh! My Cod in Lisbon, said being indoors with unmasked tourists while eating does not worry her, though she’s heard concerns from other Portuguese people that the return of foreigners could threaten Portugal’s low case numbers, despite tourists testing negative before they can fly. “You have people thinking about it, of course,” she said. But, she added: “I think people in general are quite happy to see the tourism come back.” One month ago, she would run maybe one tour per week. Now it’s up to 10 per week, with about 70 percent of her bookings from Britain, she said. In addition to British tourists, Portugal has also welcomed back visitors from the European Union. For Sara Guerreiro, who owns a ceramics shop in the Feira da Ladra flea market in the winding Alfama district, last Saturday was more of a tease of normality. Looking outside her shop, she saw maybe 10 percent of the pre-pandemic foot traffic through the twice-weekly market, which sells miscellaneous items to locals alongside artwork and trinkets to tourists. Image A tourist photographs the famous 28 tram in Lisbon’s historic heart, Baixa.Credit...Ana Brigida for The New York Times But she said Lisbon could use a better balance in how many tourists it welcomes, because “how it was before was also too much.” Overall, a mere trickle of tourists have returned to Portugal so far compared to the pre-virus hordes. Those who made the trip were able to enjoy the city as few have: without swarms of other tourists to jostle with. At the ornate Praça do Comércio, a historic square typically packed with visitors, just a few dozen lingered. You could easily take a wide-angle photo outside Belém Tower, a popular landmark, at noon on Sunday with no other people in it. The line for custard tarts at nearby Pastéis de Belém, typically an out-the-door affair, passed in a few brief minutes Sunday morning. At Tasco do Chico, renowned for its live fado music, a spot at the bar was available one minute before Saturday night’s first performance began. Image Belém Tower, one of the most famous monuments in Lisbon, has few tourists still. Credit...Ana Brigida for The New York Times In one lively scene reminiscent of pre-pandemic freedom, tourists and locals alike converged Saturday night in Bairro Alto, with bars and restaurants packed with revelers until the 10:30 p.m. curfew. Nicci Howson, 65, said she was surrounded by Portuguese people dancing in Cervejaria do Bairro, a restaurant in that neighborhood, the first time she had danced outside her home in a year. “You could see the elation on people’s faces to just let loose,” she said. At 10:30 p.m., when some Portuguese might just be sitting down to dinner in normal times, the bars closed and sent packs of people dancing and singing tightly together in the narrow streets, until they were shooed away by police on motorcycles about five minutes later. The revelers lingered in the nearby Luís de Camões Square until 11:30 p.m., when officers dispersed the group. But during the day, there were no such crowds to contend with. Mark Boulle, 38, from Oxford, England, said he typically tries to avoid crowds while traveling, so the trip was in that respect a dream. When he took a day trip to Sintra, a nearby town with postcard-ready palaces and castles, on Monday, “for the first half of the day I virtually had the whole place to myself,” he said. But he was dismayed by the widespread use of masks outdoors in Lisbon — a sharp departure from behaviors in Britain, where the government has never suggested wearing masks outside and most people do not. It was a source of tension for both visitors and the Portuguese. Image British tourists in Lisbon did not have competition for a prime view at the ancient São Jorge Castle. Credit...Ana Brigida for The New York Times Using masks outdoors is mandatory in Portugal, with violators in some locations, including beaches , facing fines. At the Castelo de São Jorge, an 11th century castle with sweeping views of the city, a security guard roamed the grounds outside, instructing the few tourists there to put masks on while standing far away from others. A bookseller at an open-air market in Baixa grumbled that the tourists ought to comply with local attitudes and customs about masks, instead of bringing their own ideas abroad. But Mr. Boulle said he wanted the sun on his face. As he went to buy his ticket at the Jerónimos Monastery, a popular tourist attraction, he recalled, a security guard stopped him before he could buy his ticket, asking him to put a mask on. Mr. Boulle replied that he has asthma, and he couldn’t wear one because he’d have trouble breathing. “That isn’t true, but I just wanted to see,” he said. “In England you can always say that.” No such luck, as the security guard insisted. Frederico Almeida, the general manager of the Albatroz Hotel in the nearby beach town of Cascais, said he and his staff has had to remind visitors from Britain of the requirements. Despite these issues, he’s happy to see British tourists again. They are the top market for the area, he said, and their return has been swift. The 42-room hotel was at about 20 percent occupancy two weeks ago; now it’s up to about 80 percent. “All of a sudden, in the last two weeks, it’s as if we’ve turned back to normality,” he said. “It’s wonderful.” THE WORLD IS REOPENING. LET’S GO, SAFELY. Follow New York Times Travel on Instagram , Twitter and Facebook . And sign up for our Travel Dispatch newsletter : Each week you’ll receive tips on traveling smarter, stories on hot destinations and access to photos from all over the world. Advertisement

Alfama Frequently Asked Questions (FAQ)

  • When was Alfama founded?

    Alfama was founded in 2005.

  • Where is Alfama's headquarters?

    Alfama's headquarters is located at Taguspark, Porto Salvo.

  • What is Alfama's latest funding round?

    Alfama's latest funding round is Acquired.

  • How much did Alfama raise?

    Alfama raised a total of $4.18M.

  • Who are the investors of Alfama?

    Investors of Alfama include Proterris, InovCapital, Sussex Research, Beta Capital Sociedade de Capital de Risco S.A., PME Investimentos and 5 more.

  • Who are Alfama's competitors?

    Competitors of Alfama include Humanetics, CoImmune, Akebia Therapeutics, Pearl Therapeutics, Micromet and 12 more.

Compare Alfama to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

Calyx Therapeutics

Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.

Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.